Entrada Therapeutics Inc (TRDA) — Tangible Net Worth Ratio
Entrada Therapeutics Inc (TRDA) has a Tangible Net Worth Ratio of 100.0% as of September 2025. This metric is calculated by deducting intangible assets ($0.00) from net assets ($340.72 Million) and expressing it as a percentage of total net assets. A higher ratio means that more of the company's equity is backed by tangible, balance-sheet-verifiable assets rather than goodwill, patents, or brand value. For live market cap and overall valuation, see Entrada Therapeutics Inc market capitalisation.
Tangible NW Ratio
Net Assets (Equity)
Intangible Assets
Total Assets
Entrada Therapeutics Inc Tangible Net Worth Ratio (2021–2024)
This chart shows how Entrada Therapeutics Inc's Tangible Net Worth Ratio has changed across 4 annual periods from 2021 to 2024. As of September 2025, the ratio stands at 100.0%, reflecting net assets of $340.72 Million with intangible assets of $0.00 USD. Also explore TRDA year-over-year net asset growth to track the company's year-over-year net asset growth rate.
Annual Tangible Net Worth Ratio for Entrada Therapeutics Inc (2021–2024)
The table below presents the year-by-year Tangible Net Worth Ratio for Entrada Therapeutics Inc from 2021 to 2024, covering 4 annual filings. Each row shows net assets, intangible assets, total assets, the tangible net worth ratio, and the change in percentage points versus the prior year. See Entrada Therapeutics Inc free cash flow to debt ratio to measure the company's free cash flow as a share of total liabilities.
| Year | Tangible NW Ratio | Net Assets (USD) | Intangible Assets | Total Assets | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 100.0% | $428.68 Million | $0.00 | $526.32 Million | ▲ +0.0 pp |
| 2023 | 100.0% | $242.36 Million | $0.00 | $469.19 Million | ▲ +0.0 pp |
| 2022 | 100.0% | $212.55 Million | $0.00 | $252.06 Million | ▲ +0.0 pp |
| 2021 | 100.0% | $298.72 Million | $0.00 | $305.83 Million | — |